对于早期肺癌生物标志物的有效和可解释的集体学习框架
IEEE transactions on computational biology and bioinformatics
|September 2, 2025
概括
这项研究引入了一种有效和可解释的集体学习框架 (EEE框架),用于早期检测非小细胞肺癌 (NSCLC). 该框架使用可解释的人工智能增强生物标志物发现和解释性,提高诊断准确性.
科学领域:
- 计算生物学和生物信息学
- 医学的人工智能
- 瘤学和癌症研究
背景情况:
- 早期发现非小细胞肺癌 (NSCLC) 对患者的治疗结果至关重要.
- 机器学习模型在生物标志物发现中的解释性仍然是一个重大挑战.
- 基因表达数据提供了识别NSCLC生物标志物的潜力,但需要复杂的分析.
研究的目的:
- 为早期发现NSCLC生物标志物提出一个高效和可解释的整体学习框架 (EEE框架).
- 解决NSCLC检测模型中的准确性和可解释性之间的权衡问题.
- 使用可解释的人工智能识别和理解NSCLC生物标志物的重要性和相互关系.
主要方法:
- 使用五个可解释的基础学习者 (决策树,随机森林,XGBoost,AdaBoost,高斯的天真贝叶斯) 开发了一个集体学习模型.
- 使用六种可解释的人工智能 (XAI) 方法进行生物标志物识别 (本地,全球,内在,后期可解释性).
- 在TCGA RNA_seq数据集和自建甲基化数据集上验证了EEE框架.
主要成果:
- 组合学习模型实现了高分类性能,F1分数为0.9983 (AUC:0.9993) 和0.8462 (AUC:0.9249) 在各自的数据集上.
- 全球和本地可解释可视化提供了有关NSCLC生物标志物重要性,相互关系和因果关系的重要见解.
- 该EEE框架在NSCLC检测结果中表现出强大的概括能力和增强的解释性.
结论:
- 该EEE框架有效地平衡了早期NSCLC检测和生物标志物的准确性和可解释性.
- 可解释的AI方法显著提高了NSCLC复杂生物标志物数据的理解.
- 这一框架为改善NSCLC诊断和指导进一步研究提供了有希望的工具.
更多相关视频
相关概念视频
01:25Statistical Methods for Analyzing Epidemiological Data
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...